摘要
神经内分泌肿瘤（NETs）是-组异质性肿瘤，18F—FDG不是NETs的理想显像剂，大多数NETs分化良好、生长缓慢，通常糖代谢水平很低，18F—FDGPET显像对分化差、侵袭性强的神经内分泌癌的诊断灵敏度较高。11C-5-羟基色氨酸、18F-氟代多巴、mF-多巴和11C-多巴等胺前体类PET显像剂在类癌、胰岛细胞癌、嗜铬细胞瘤、副神经节瘤、甲状腺髓样癌、高胰岛素血症等实体肿瘤的成像诊断中具有独特价值。最近研发的mGa—DOTA—peptide（其中，DOTA为1，4，7，10-四氮杂环十二烷-N, N′, N′, N′″-四乙酸）中几种新型的生长抑素类似物PET已用于NETs的诊断和肽受体的放射性核素治疗。68Ga—DOTA—peptidePET／CT显像可改善半数以上NETs患者的病程和治疗计划，是-种极具发展前景的NETs显像模式。
Neuroendocrine tumors （NETs） are a group of heterogeneous tumors, 18F-FDG is not an ideal tracer for NETs. Most of the NETs are well-differentiated, slow growth, low levels of glucose metabolism. tSF-FDG PET usually show high sensitivity for poorly-differentiated and invasive neuroendocrine carcinonia. Other pro-amine PET agents such as HC-5-hydroxytryptophan, JSF-fluoro-dopa, lSF-dopa and C-dopa have great values for the diagnosis of careinoid, islet cell carcinoma, pheochromocytoma, paraganglioma, medullary thyroid careinoma, hyperinsulinemia and other solid NETs. Some new developed 6SGa-DOTA-peptide [1,4,7,10-tetraazacyclododecane-N, N′, N′, N′″-tetraacetic acid （DOTA）] somatostatin PET tracers had already been used in NETs diagnosis and peptide receptor radionuclide therapy. The preliminary results show that 68Ga-DOTA-peptide PET/CT can improve the course and treatment program design in more than half of NETs patients, which is a pronfising NETs imaging mode.
出处
《国际放射医学核医学杂志》
2013年第3期186-192,共7页
International Journal of Radiation Medicine and Nuclear Medicine
